In a phase II study conducted on 186 patients with chronic-phase CML, after 8 months of continuous dasatinib treatment, 52% and 60% of patients experienced elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity, respectively.[3] A similar result is also observed in another phase II study performed on 116 patients with CML in myeloid blast crisis (MBC) or lymphoid blast crisis (LBC). The gene discussed is GPT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.